Updated on 2025/06/12

写真a

 
UEKI Hideo
 
Organization
Department of Comprehensive Technical Solutions Technical Expert staff
Position
Technical Expert staff
External link

Degree

  • Master of Agricultural Science ( 2003.3   Okayama University )

Research Areas

  • Life Science / Urology

 

Papers

  • The Necroptotic Process-Related Signature Predicts Immune Infiltration and Drug Sensitivity in Kidney Renal Papillary Cell Carcinoma. International journal

    Wenfeng Lin, Ruizhi Xue, Hideo Ueki, Peng Huang

    Current cancer drug targets   2024.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: It remains controversial whether the current subtypes of kidney renal papillary cell carcinoma (KIRP) can be used to predict the prognosis independently. OBJECTIVE: This observational study aimed to identify a risk signature based on necroptotic pro-cess-related genes (NPRGs) in KIRP. METHODS: In the training cohort, LASSO regression was applied to construct the risk signature from 158 NPRGs, followed by the analysis of Overall Survival (OS) using the Kaplan-Meier method. The signature accuracy was evaluated by the Receiver Operating Characteristic (ROC) curve, which was further validated by the test cohort. Wilcoxon test was used to compare the expressions of immune-related genes, neoantigen genes, and immune infiltration between differ-ent risk groups, while the correlation test was performed between NPRGs expressions and drug sensitivity. Gene set enrichment analysis was used to investigate the NPRGs' signature's biologi-cal functions. RESULTS: We finally screened out 4-NPRGs (BIRC3, CAMK2B, PYGM, and TRADD) for con-structing the risk signature with the area under the ROC curve (AUC) reaching about 0.8. The risk score could be used as an independent OS predictor. Consistent with the enriched signaling, the NPRGs signature was found to be closely associated with neoantigen, immune cell infiltration, and immune-related functions. Based on NPRGs expressions, we also predicted multiple drugs potentially sensitive or resistant to treatment. CONCLUSION: The novel 4-NPRGs risk signature can predict the prognosis, immune infiltration, and therapeutic sensitivity of KIRP.

    DOI: 10.2174/0115680096286503240321040556

    PubMed

    researchmap

  • Significance of UGT1A6, UGT1A9, and UGT2B7 genetic variants and their mRNA expression in the clinical outcome of renal cell carcinoma. International journal

    Jun Matsumoto, Anzu Nishimoto, Shogo Watari, Hideo Ueki, Shoya Shiromizu, Naohiro Iwata, Tatsuaki Takeda, Soichiro Ushio, Makoto Kajizono, Masachika Fujiyoshi, Toshihiro Koyama, Motoo Araki, Koichiro Wada, Yoshito Zamami, Yasutomo Nasu, Noritaka Ariyoshi

    Molecular and cellular biochemistry   478 ( 8 )   1779 - 1790   2022.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    UDP-glucuronosyltransferase (UGT) metabolizes a number of endogenous and exogenous substrates. Renal cells express high amounts of UGT; however, the significance of UGT in patients with renal cell carcinoma (RCC) remains unknown. In this study, we profile the mRNA expression of UGT subtypes (UGT1A6, UGT1A9, and UGT2B7) and their genetic variants in the kidney tissue of 125 Japanese patients with RCC (Okayama University Hospital, Japan). In addition, we elucidate the association between the UGT variants and UGT mRNA expression levels and clinical outcomes in these patients. The three representative genetic variants, namely, UGT1A6 541A > G, UGT1A9 i399C > T, and UGT2B7-161C > T, were genotyped, and their mRNA expression levels in each tissue were determined. We found that the mRNA expression of the three UGTs (UGT1A6, UGT1A9, and UGT2B7) are significantly downregulated in RCC tissues. Moreover, in patients with RCC, the UGT2B7-161C > T variant and high UGT2B7 mRNA expression are significantly correlated with preferable cancer-specific survival (CSS) and overall survival (OS), respectively. As such, the UGT2B7-161C > T variant and UGT2B7 mRNA expression level were identified as significant independent prognostic factors of CSS and CSS/OS, respectively. Taken together, these findings indicate that UGT2B7 has a role in RCC progression and may, therefore, represent a potential prognostic biomarker for patients with RCC.

    DOI: 10.1007/s11010-022-04637-4

    PubMed

    researchmap

  • Identification of MICALL2 as a Novel Prognostic Biomarker Correlating with Inflammation and T Cell Exhaustion of Kidney Renal Clear Cell Carcinoma

    Wenfeng Lin, Wenwei Chen, Jisheng Zhong, Hideo Ueki, Abai Xu, Masami Watanabe, Motoo Araki, Chunxiao Liu, Yasutomo Nasu, Peng Huang

    JOURNAL OF CANCER   13 ( 3 )   1214 - 1228   2022

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.7150/jca.66922

    Web of Science

    researchmap

  • Relevance of CYP3A5 Expression on the Clinical Outcome of Patients With Renal Cell Carcinoma. Reviewed International journal

    Jun Matsumoto, Yumi Kotera, Shogo Watari, Koichi Takeuchi, Hideo Ueki, Toshihiro Koyama, Koichiro Wada, Masachika Fujiyoshi, Yasutomo Nasu, Noritaka Ariyoshi

    Anticancer research   41 ( 5 )   2511 - 2521   2021.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: This study aimed to elucidate the detailed characteristics of CYP3A5 expression and the association between CYP3A5 expression and clinical outcomes in patients with renal cell carcinoma (RCC). PATIENTS AND METHODS: This study retrospectively enrolled 124 Japanese patients with RCC treated at the Okayama University Hospital. The commonest CYP3A5 gene polymorphism, CYP3A5*3, and expression levels of CYP3A5 mRNA and protein in each tissue were examined. RESULTS: Expression of CYP3A5 mRNA and protein in RCC tissues was significantly down-regulated compared to that in adjacent normal tissues. High level of CYP3A5 mRNA expression significantly extended cancer-specific survival (p=0.004) and overall survival (p=0.002). The CYP3A5 mRNA expression level was identified as a significant independent prognostic factor for both cancer-specific survival and overall survival. CONCLUSION: CYP3A5 could serve as a potential marker for prognostication and treatment planning for patients with RCC.

    DOI: 10.21873/anticanres.15029

    PubMed

    researchmap

  • Repurposing of posaconazole as a hedgehog/SMO signaling inhibitor for embryonal rhabdomyosarcoma therapy. International journal

    Jingkai Sun, Wenfeng Lin, Chaoming Li, Hideo Ueki, Ruizhi Xue, Takuya Sadahira, Hao Hu, Koichiro Wada, Na Li, Chunxiao Liu, Motoo Araki, Abai Xu, Peng Huang

    American journal of cancer research   11 ( 9 )   4528 - 4540   2021

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Posaconazole (POS) is a novel antifungal agent, which has been repurposed as an anti-tumor drug for its potential inhibition of Hedgehog signaling pathway. Hedgehog pathway is reported to be abnormally activated in embryonal rhabdomyosarcoma (ERMS), this study aimed to reveal whether POS could inhibit Hedgehog signaling pathway in ERMS. Following POS treatment, XTT viability assay was used to determine the cell proliferation of ERMS cell lines. Protein changes related to Hedgehog signaling, cell cycle and autophagy were detected by Western blot. The cell cycle distribution was analyzed by flow cytometry. Moreover, a subcutaneous tumor mouse model of ERMS was established to assess the anti-tumor effect of POS. POS was found to inhibit tumor progression by inducing G0/G1 arrest and autophagy of RD, RMS-YM, and KYM-1 cells dose-dependently. Western blot demonstrated that POS downregulated the expressions of SMO, Gli1, c-Myc, CDK4, and CDK6, while upregulated the expressions of autophagy-related proteins. Immunofluorescence microscopy revealed a significant increase of LC3B puncta in POS-treated ERMS cells. Furthermore, POS treatment led to a significant inhibition of tumor growth in mice bearing ERMS. Our findings could provide a theoretical basis and have important clinical implications in developing POS as a promising agent against ERMS by targeting Hedgehog pathway.

    PubMed

    researchmap

  • Tumor suppressor REIC/Dkk‑3 and its interacting protein SGTA inhibit glucocorticoid receptor to nuclear transport Reviewed

    Takehiro Iwata, Takuya Sadahira, Kazuhiko Ochiai, Hideo Ueki, Takanori Sasaki, Peng Haung, Motoo Araki, Toyohiko Watanabe, Yasutomo Nasu, Masami Watanabe

    Experimental and Therapeutic Medicine   2020.5

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Spandidos Publications  

    DOI: 10.3892/etm.2020.8819

    researchmap

  • Role of Egr1 on Pancreatic Endoderm Differentiation Reviewed

    Tsugata Takako, Nikoh Naruo, Kin Tatsuya, Miyagi-Shiohira Chika, Nakashima Yoshiki, Saitoh Issei, Noguchi Yasufumi, Ueki Hideo, Watanabe Masami, Kobayashi Naoya, Shapiro Andrew, M. James, Noguchi Hirofumi

    CELL MEDICINE   10   2018.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1177/2155179017733177

    Web of Science

    researchmap

  • Induction of cells with prostate cancer stem-like properties from mouse induced pluripotent stem cells via conditioned medium. Reviewed International journal

    Naijin Xu, Xiezhao Li, Masami Watanabe, Hideo Ueki, Hao Hu, Na Li, Motoo Araki, Koichiro Wada, Abai Xu, Chunxiao Liu, Yasutomo Nasu, Peng Huang

    American journal of cancer research   8 ( 8 )   1624 - 1632   2018

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Web of Science

    PubMed

    researchmap

  • Properties of the feline tumour suppressor reduced expression in immortalized cells (REIC/Dkk-3) Reviewed

    K. Ochiai, H. Oda, S. Shono, Y. Kato, S. Sugihara, S. Nakazawa, D. Azakami, M. Michishita, E. Onozawa, M. Bonkobara, T. Sako, L. Shun-Ai, H. Ueki, M. Watanabe, T. Omi

    VETERINARY AND COMPARATIVE ONCOLOGY   15 ( 4 )   1181 - 1186   2017.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/vco.12254

    Web of Science

    Scopus

    PubMed

    researchmap

  • Robust cancer-specific gene expression by a novel cassette with hTERT and CMV promoter elements Reviewed

    Masakiyo Sakaguchi, Takuya Sadahira, Hideo Ueki, Rie Kinoshita, Hitoshi Murata, Ken-Ichi Yamamoto, Junichiro Futami, Yasutomo Nasu, Kazuhiko Ochiai, Hiromi Kumon, Nam-Ho Huh, Masami Watanabe

    ONCOLOGY REPORTS   38 ( 2 )   1108 - 1114   2017.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3892/or.2017.5710

    Web of Science

    PubMed

    researchmap

  • The Downregulation of the Expression of CD147 by Tumor Suppressor REIC/Dkk-3, and Its Implication in Human Prostate Cancer Cell Growth Inhibition Reviewed

    Akihiro Mori, Masami Watanabe, Takuya Sadahira, Yasuyuki Kobayashi, Yuichi Ariyoshi, Hideo Ueki, Koichiro Wada, Kazuhiko Ochiai, Shun-Ai Li, Yasutomo Nasu

    ACTA MEDICA OKAYAMA   71 ( 2 )   135 - 142   2017.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.18926/AMO/54982

    Web of Science

    PubMed

    researchmap

  • Tumor suppressor REIC/DKK-3 and co-chaperone SGTA: Their interaction and roles in the androgen sensitivity Reviewed

    Kazuhiko Ochiai, Masami Morimatsu, Yuiko Kato, Toshina Ishiguro-Oonuma, Chihiro Udagawa, Oumaporn Rungsuriyawiboon, Daigo Azakami, Masaki Michishita, Yuichi Ariyoshi, Hideo Ueki, Yasutomo Nasu, Hiromi Kumon, Masami Watanabe, Toshinori Omi

    ONCOTARGET   7 ( 3 )   3273 - 3286   2016.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.18632/oncotarget.6488

    Web of Science

    PubMed

    researchmap

  • A vaccine strategy with multiple prostatic acid phosphatase-fused cytokines for prostate cancer treatment Reviewed

    Kei Fujio, Masami Watanabe, Hideo Ueki, Shun-Ai Li, Rie Kinoshita, Kazuhiko Ochiai, Junichiro Futami, Toyohiko Watanabe, Yasutomo Nasu, Hiromi Kumon

    ONCOLOGY REPORTS   33 ( 4 )   1585 - 1592   2015.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3892/or.2015.3770

    Web of Science

    PubMed

    researchmap

  • Potential Factors for the Differentiation of ESCs/iPSCs Into Insulin-Producing Cells. Reviewed

    Tsugata T, Nikoh N, Kin T, Saitoh I, Noguchi Y, Ueki H, Watanabe M, James Shapiro AM, Noguchi H

    Cell medicine   7 ( 2 )   83 - 93   2015.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3727/215517914X685178

    Web of Science

    PubMed

    researchmap

  • Significant association between the Axin2 rs2240308 single nucleotide polymorphism and the incidence of prostate cancer Reviewed

    Chao Ma, Chunxiao Liu, Peng Huang, Haruki Kaku, Jie Chen, Kai Guo, Hideo Ueki, Akiko Sakai, Yasutomo Nasu, Hiromi Kumon, Kenji Shimizu, Masami Watanabe

    ONCOLOGY LETTERS   8 ( 2 )   789 - 794   2014.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3892/ol.2014.2177

    Web of Science

    PubMed

    researchmap

  • Dramatic Increase in Expression of a Transgene by Insertion of Promoters Downstream of the Cargo Gene Reviewed

    Masakiyo Sakaguchi, Masami Watanabe, Rie Kinoshita, Haruki Kaku, Hideo Ueki, Junichiro Futami, Hitoshi Murata, Yusuke Inoue, Shun-Ai Li, Peng Huang, Endy Widya Putranto, I. Made Winarsa Ruma, Yasutomo Nasu, Hiromi Kumon, Nam-ho Huh

    MOLECULAR BIOTECHNOLOGY   56 ( 7 )   621 - 630   2014.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s12033-014-9738-0

    Web of Science

    PubMed

    researchmap

  • Immunological aspects of REIC/Dkk-3 gene therapy : the mechanism of the robust anti-tumor effects. Reviewed

    Masami Watanabe, Peng Huang, Fernando Abarzua, Haruki Kaku, Katsumi Sasaki, Hideo Ueki, Toyohiko Wananabe, Yasutomo Nasu, Hiromi Kumon

    JOURNAL OF GENE MEDICINE   16 ( 7-8 )   226 - 227   2014.7

     More details

    Language:English  

    Web of Science

    researchmap

  • A novel gene expression system strongly enhances the anticancer effects of a REIC/Dkk-3-encoding adenoviral vector Reviewed

    Masami Watanabe, Masakiyo Sakaguchi, Rie Kinoshita, Haruki Kaku, Yuichi Ariyoshi, Hideo Ueki, Ryuta Tanimoto, Shin Ebara, Kazuhiko Ochiai, Junichiro Futami, Shun-Ai Li, Peng Huang, Yasutomo Nasu, Nam-Ho Huh, Hiromi Kumon

    ONCOLOGY REPORTS   31 ( 3 )   1089 - 1095   2014.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3892/or.2013.2958

    Web of Science

    PubMed

    researchmap

  • Cancer stem cell-like characteristics of a CD133+ subpopulation in the J82 human bladder cancer cell line. Reviewed International journal

    Peng Huang, Masami Watanabe, Haruki Kaku, Hideo Ueki, Hirofumi Noguchi, Morito Sugimoto, Takeshi Hirata, Hiroshi Yamada, Kohji Takei, Shaobo Zheng, Kai Xu, Yasutomo Nasu, Yasuyuki Fujii, Chunxiao Liu, Hiromi Kumon

    Molecular and clinical oncology   1 ( 1 )   180 - 184   2013.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Cancer stem cells (CSCs) are thought to be crucial for understanding the biological roots of cancer, and are of increasing importance as a target for new anticancer agents. According to an expression analysis of the cell surface antigens of various types of cancer, CD133 is considered to be a potential marker of cancer stemness. In this study, a human urinary bladder cancer cell line (J82) was used to analyze the cancer stem cell-like characteristics of CD133+ bladder cancer cells in vitro and in vivo. The CD133 expression in the J82 cells was examined and the cells were immunomagnetically categorized into positive and negative subsets. The CD133- and CD133+ subsets were phenotypically divergent with regard to the cell growth pattern, while CD133+ cells tended to colonize during their growth. In CD133+ cells, the pluripotent stem cell factors Oct-4 and Sox-2 were upregulated, and a statistically significant proliferation increase was observed when compared to CD133- cells. The CD133+ subpopulation was more tolerant to the chemotherapeutic agent cisplatin, and Bacillus Calmette-Guérin (BCG), an agent instilled intravesically to treat bladder cancer. In addition, CD133+ J82 cells were more resistant to radiation treatment when compared to CD133- cells. The in vivo tumorigenesis of the CD133- and CD133+ subsets of J82 cancer cells was also examined by subcutaneously injecting them into nude mice. The tumor growth was more aggressive in the CD133+ subpopulation, showing a significant difference in the tumorigenic potential in these subsets. In conclusion, J82 human bladder cancer cells include CD133- and CD133+ subpopulations, while the CD133 molecule is a potential marker of the potential malignancy of human bladder cancer. In the present study, the CD133+ subpopulation was herein demonstrated to have certain characteristics consistent with those of cancer stem cells.

    DOI: 10.3892/mco.2012.29

    PubMed

    researchmap

  • Preclinical biodistribution and safety study of reduced expression in immortalized cells/Dickkopf-3-encoding adenoviral vector for prostate cancer gene therapy Reviewed

    Morito Sugimoto, Masami Watanabe, Haruki Kaku, Shun-Ai Li, Hirofumi Noguchi, Hideo Ueki, Masakiyo Sakaguchi, Nam-Ho Huh, Yasutomo Nasu, Hiromi Kumon

    ONCOLOGY REPORTS   28 ( 5 )   1645 - 1652   2012.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3892/or.2012.2001

    Web of Science

    PubMed

    researchmap

  • A novel gene expression system for detecting viable bladder cancer cells Reviewed

    Hideo Ueki, Masami Watanabe, Haruki Kaku, Peng Huang, Shun-Ai Li, Kazuhiko Ochiai, Takeshi Hirata, Hirofumi Noguchi, Hiroshi Yamada, Kohji Takei, Yasutomo Nasu, Yuji Kashiwakura, Hiromi Kumon

    INTERNATIONAL JOURNAL OF ONCOLOGY   41 ( 1 )   135 - 140   2012.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3892/ijo.2012.1417

    Web of Science

    PubMed

    researchmap

  • Implications of transcriptional factor, OCT-4, in human bladder malignancy and tumor recurrence Reviewed

    Peng Huang, Jie Chen, Lei Wang, Yanqun Na, Haruki Kaku, Hideo Ueki, Katsumi Sasaki, Ken Yamaguchi, Kai Zhang, Takashi Saika, Yasutomo Nasu, Masami Watanabe, Hiromi Kumon

    MEDICAL ONCOLOGY   29 ( 2 )   829 - 834   2012.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s12032-011-9962-4

    Web of Science

    PubMed

    researchmap

  • Advanced two-step transcriptional amplification as a novel method for cancer-specific gene expression and imaging Reviewed

    Masami Watanabe, Hideo Ueki, Kazuhiko Ochiai, Peng Huang, Yasuyuki Kobayashi, Yasutomo Nasu, Katsumi Sasaki, Haruki Kaku, Yuji Kashiwakura, Hiromi Kumon

    ONCOLOGY REPORTS   26 ( 4 )   769 - 775   2011.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3892/or.2011.1371

    Web of Science

    PubMed

    researchmap

  • Tumor suppressor REIC/Dkk-3 interacts with the dynein light chain, Tctex-1 Reviewed

    Kazuhiko Ochiai, Masami Watanabe, Hideo Ueki, Peng Huang, Yasuyuki Fujii, Yasutomo Nasu, Hirofumi Noguchi, Takeshi Hirata, Masakiyo Sakaguchi, Nam-ho Huh, Yuji Kashiwakura, Haruki Kaku, Hiromi Kumon

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   412 ( 2 )   391 - 395   2011.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.bbrc.2011.07.109

    Web of Science

    PubMed

    researchmap

  • Expression pattern of REIC/Dkk-3 in various cell types and the implications of the soluble form in prostatic acinar development Reviewed

    Kai Zhang, Masami Watanabe, Yuji Kashiwakura, Shun-Al Li, Kohei Edamura, Peng Huang, Ken Yamaguchi, Yasutomo Nasu, Yasuyuki Kobayashi, Masakiyo Sakaguchi, Kazuhiko Ochiai, Hiroshi Yamada, Kohji Takei, Hideo Ueki, Nam-Ho Huh, Ming Li, Haruki Kaku, Yanqun Na, Hiromi Kumon

    INTERNATIONAL JOURNAL OF ONCOLOGY   37 ( 6 )   1495 - 1501   2010.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3892/ijo_00000802

    Web of Science

    PubMed

    researchmap

▼display all

MISC

  • Advanced two-step transcriptional amplification as a novel method for cancer-specific gene expression and imaging

    H. Kaku, H. Ueki, Y. Ariyoshi, S. Li, P. Huang, Y. Nasu, H. Kumon, M. Watanabe

    HUMAN GENE THERAPY   24 ( 12 )   A154 - A154   2013.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

    researchmap

  • 植物シスタチン遺伝子導入による耐虫性ダイズの作出

    山田聖, 植木英雄, 喜多洋一, 西沢けいと, 黒田昌治, 与座宏一, 北山雅彦, 石本政男

    日本植物生理学会年会要旨集   46th ( 0 )   227 - 491   2005.3

     More details

    Language:Japanese   Publisher:日本植物生理学会  

    Bean bug,<I>Riptortus clavatus</I>, causes a serious damage of soybean production. The insect pest utilizes cysteine proteinases for protein digestion. In contrast, plants contain proteinous inhibitors, cystatins, against endogenous and exogenous cysteine proteinases including insect digestive proteases. In this research, we produced transgenic soybeans overexpressing plant cystatins to confer the insect resistance. We used three plant cystatins, OC1, mCC1 and JTC, from rice, corn, and Job's tears, respectively. Each of the cystatin genes was connected with a seed specific promoter derived from soybean 7S globulin gene or CaMV35S promoter, and <I>nos</I>-terminator, and the resultant cassette was inserted between the green fluorescence protein gene and the hygromycin resistance gene in a pUHG plasmid vector. The plasmids were introduced into soybean embryogenic cells by particle bombardment. Several transgenic plants were obteined by introduction of these constructs and we are now developing fixed lines for transgenes to analyze the resistance to <I>R. clavatus</I>.

    DOI: 10.14841/jspp.2005.0.491.0

    CiNii Article

    J-GLOBAL

    researchmap

Presentations

  • ダイズシストセンチュウ抵抗性遺伝子型を判別する分子マーカーの開発

    植木 英雄

    日本育種学会 第105回講演会  2004 

     More details

  • サツマイモにおけるレトロトランスポソンLTR配列の解析

    植木 英雄

    日本育種学会 第100回講演会  2001 

     More details

Industrial property rights

  • REIC/Dkk−3タンパク質の部分領域ポリペプチド

    公文 裕巳, 渡部 昌実, 二見 淳一郎, 藤井 康之, 植木 英雄, 落合 和彦

     More details

    Applicant:国立大学法人 岡山大学, 桃太郎源株式会社

    Application no:特願2012-522733  Date applied:2011.7.1

    Announcement no:WO2012-002582  Date announced:2012.1.5

    Patent/Registration no:特許第5936129号  Date issued:2016.5.20

    J-GLOBAL

    researchmap

Research Projects

  • Oncolytic virus の多元的制癌性の解明と革新的癌治療への展開

    Grant number:22K09526  2022.04 - 2025.03

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    植木 英雄

      More details

    Grant amount:\3900000 ( Direct expense: \3000000 、 Indirect expense:\900000 )

    researchmap

  • 骨髄由来免疫抑制細胞の抗癌免疫逃避機構の解明に基づく革新的癌創薬の探索

    Grant number:21K09371  2021.04 - 2024.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    黄 鵬

      More details

    Grant amount:\4160000 ( Direct expense: \3200000 、 Indirect expense:\960000 )

    癌の研究開発において、癌免疫逃避機構に関する最近の注目すべき研究として、骨髄由来免疫抑制細胞(MDSC: myeloid-derived suppresser cell)が、癌に対する免疫監視機構や抗腫瘍免疫を負に制御して癌の悪性進展の中心的役割を担っていることが明らかにされつつある。本申請研究では、骨髄由来免疫抑制細胞の抗癌免疫逃避機構の解明に基づく革新的癌創薬の探索を目指している。本年度は、
    ①前立腺がん担癌マウスより末梢血を採収後FACS AriaでMDSSC細胞を分離し、MDSC細胞の表面マーカーの確認を行った。分離したMDSC細胞に対するREIC/Dkk-3タンバク質の抑制効果の観点から解析した。さらに、Ad-REICの抗癌作用に基づく免疫逃避応答に関する機序を解明し、その有効性を検証した。
    ②分離したMDSC細胞にREIC/Dkk-3タンパク質を作用させ、1分、30分、1時間、6時間、24時間後細胞内タンパク質を抽出し、または特異的siRNAによりノックダウンさせ、遺伝子-タンパク質発現変動をマイクロアレイやタンパク質抗体アレイ等により解析した。また、Western blot法により関連したパスウェイ内の各種タンパク質およびそのリン酸化の動態を実験した。
    ③細胞核内の標的遺伝子群(転写されるタンパク質群)の同定を行い、REIC/Dkk-3とMDSC細胞膜上での結合分子・受容体の同定解析を行った。

    researchmap

  • 新規の癌抗原CD147を標的とする適応免疫最適化と尿路性器腫瘍での応用展開

    2018.04 - 2022.03

    日本学術振興会  科学研究費/基盤研究(B) 

    那須 保友

      More details

    Grant type:Competitive

    researchmap

  • 制限増殖型アデノウィルスを用いた次世代遺伝子治療の基盤研究

    2018.04 - 2021.03

    日本学術振興会  科学研究費/基盤研究(C) 

    小林 泰之

      More details

    Grant type:Competitive

    researchmap

  • REIC/Dkk-3遺伝子による前立腺細胞増殖制御機構に関する研究

    2018.04 - 2021.03

    日本学術振興会  科学研究費/基盤研究(C) 

    高本 篤

      More details

    Grant type:Competitive

    researchmap

  • 膀胱再生を目指した排尿平滑筋幹細胞の創出とその応用

    2017.04 - 2021.03

    日本学術振興会  科学研究費/基盤研究(C) 

    渡邉 豊彦

      More details

    Grant type:Competitive

    researchmap

  • 前立腺癌幹細胞を標的とした新規遺伝子治療戦略の確立

    2017.04 - 2020.03

    日本学術振興会  科学研究費/基盤研究(C) 

    黄 鵬

      More details

    Grant type:Competitive

    researchmap

  • 新規のチェックポイント阻害薬による腫瘍内免疫疲弊解除機構の解明

    2017.04 - 2020.03

    日本学術振興会  科学研究費/基盤研究(C) 

    定平 卓也

      More details

    Grant type:Competitive

    researchmap

  • Optimisation of a cancer detection and isolation technique using hTERT promoter, and establishment of its applicational foundation

    Grant number:16K11004  2016.04 - 2019.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    Ueki Hideo

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\4680000 ( Direct expense: \3600000 、 Indirect expense:\1080000 )

    A novel gene expression system that dramatically increases promoter activity while maintaining cancer specificity can be used as a new technology to strongly label and detect very few free cancer cells. The optimum conditions were also examined, and data for practical use of in vitro diagnostic methods were obtained. In addition, its usefulness has been confirmed as a technique for collecting detected free cancer cells and establishing them as cell lines.

    researchmap

  • Regeneration strategy of the functional renal corpuscle using renal stem cells

    Grant number:16K15689  2016.04 - 2019.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Challenging Exploratory Research

    Watanabe Masami, NASU YASUTOMO, UEKI HIDEO

      More details

    Grant amount:\3250000 ( Direct expense: \2500000 、 Indirect expense:\750000 )

    In this study, we recognized the difficulty of the construction of three-dimensional structure and organ volume-regeneration. We performed basic studies based on our originally developed renal stem cells derived from human primary kidney cells by transfecting iPS four factors. In order to establish the focal injection, diffusion, transplantation technique of the stem cells, we used the In situ permeation system. We also performed basic studies in terms of the mesenchymal stem cells which is relevant to the renal stem cells derived from the glomerular endothelial cells.

    researchmap

  • 腎組織幹細胞における病的ストレス制御機構の解明

    2015.04 - 2019.03

    日本学術振興会  科学研究費/基盤研究(C) 

    荒木 元朗

      More details

    Grant type:Competitive

    researchmap

  • 前立腺癌における悪性形質およびアンドロゲン不応性の一元的制御機構の解明

    2015.04 - 2019.03

    日本学術振興会  科学研究費/基盤研究(B) 

    渡部 昌実

      More details

    Grant type:Competitive

    researchmap

  • 癌増悪因子:CD147 Emmprinを標的とした新規の抗癌免疫療法の基盤の確立

    2015.04 - 2018.03

    日本学術振興会  科学研究費/基盤研究(C) 

    小林 泰之

      More details

    Grant type:Competitive

    researchmap

  • 前立腺癌抗原提示能を確立させる樹状細胞内分子機構の解明と創薬への展開

    2015.04 - 2018.03

    日本学術振興会  科学研究費/基盤研究(B) 

    那須 保友

      More details

    Grant type:Competitive

    researchmap

  • 腫瘍融解性Ad-REICを用いた新規癌ワクチン療法の開発

    2015.04 - 2017.03

    日本学術振興会  科学研究費/若手研究(B) 

    黄 鵬

      More details

    Grant type:Competitive

    researchmap

  • 尿路平滑筋幹細胞の創出と尿道括約筋再生のための基盤的研究

    2014.04 - 2017.03

    日本学術振興会  科学研究費/基盤研究(C) 

    渡邉 豊彦

      More details

    Grant type:Competitive

    researchmap

  • アンドロゲン分泌性幹細胞の創出とその応用基盤の確立

    2013.04 - 2017.03

    日本学術振興会  科学研究費/基盤研究(C) 

    杉本 盛人

      More details

    Grant type:Competitive

    researchmap

  • Development of a novel technique for the detection and isolation of disseminated cancer cells, and establishment of its application foundation

    Grant number:25462478  2013.04 - 2016.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    UEKI HIDEO, NASU Yasutomo

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\4810000 ( Direct expense: \3700000 、 Indirect expense:\1110000 )

    The purpose of this study is to conduct foundational research for development of a novel technique for the detection and isolation of disseminated cancer cells with our original gene expression systems. The reporter gene, GFP expression under the system was investigated in various cancer and normal cells and it was confirmed that the system can increase the cancer cell-specific gene expression. It was also confirmed that the GFP encoding plasmid system allowed in vitro selective visualization of floating human cancer cells in mixed cell culture containing 10000-fold more normal blood cells.

    researchmap

  • 腎組織幹細胞の誘導・分離に基づく腎再生研究基盤の確立

    2013.04 - 2016.03

    日本学術振興会  科学研究費/挑戦的萌芽研究 

    渡部 昌実

      More details

    Grant type:Competitive

    researchmap

  • 尿路癌に対する次世代癌免疫療法の創成

    2013.04 - 2015.03

    日本学術振興会  科学研究費/基盤研究(C) 

    賀来 春紀

      More details

    Grant type:Competitive

    researchmap

  • PETイメージングによるがん遺伝子治療評価モデルの構築

    2012.12 - 2013.11

    科学技術振興機構  研究成果最適展開支援プログラムA-STEP 

    黄 鵬

      More details

    Grant type:Competitive

    本申請課題は、PETイメージングによる遺伝子治療の可視化に基づく遺伝子治療の有効性、安全性の評価法の確立を目指したものであり、その目標を概ね達成できたと考える。腫瘍マーカーとイメージング装置IVISでin vivoでトレース可能なRM9細胞を用いて免疫正常マウスで皮下担がんモデルを作製し、その腫瘍内および静脈内にAd-HSV1-tk剤を投与、3日後、5日後、7日後に、PET・IVIS撮像を実施した。特に、PETイメージングによるがん遺伝子治療評価モデルの構築のために、遺伝子治療で用いるHSV1-tk遺伝子に特異的なPETレポータープローブ: [18F]FMAUを合成し、その遺伝子発現の可視化に成功した。今後、これらの遺伝子発現の可視化条件を最適化する研究を継続して行う。

    researchmap

  • REIC/Dkk―3遺伝子治療による自己癌ワクチン化療法の基盤解析

    2011.04 - 2014.03

    日本学術振興会  科学研究費/基盤研究(B) 

    公文 裕巳

      More details

    Grant type:Competitive

    researchmap

  • Basic research of smooth muscle cells generated from induced pluripotent stem cells for urethral tissue engineering.

    Grant number:23592369  2011.04 - 2014.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    WATANABE Toyohiko, WATANABE Masami, UEKI Hideo

      More details

    Grant type:Competitive

    Stress urinary incontinence is associated with a reduced quality of life. An intact urethral sphincter is mandatory to maintain urinary continence. Adult stem cell injection therapy for the regenerative repair of an impaired sphincter is currently at the forefront of research. Recently, the establishment of iPS cells has offered a novel therapeutic strategy to generate patient-specific stem cell lines. Here we have investigated whether iPS cells are able to differentiate into smooth muscle cells (SMCs) in vitro. Human iPS cell monolayers were treated with 10-5 mol/L all-trans retinoid acid (RA). After 7 days of RA treatment, we found that iPS cells highly expressed the SMC-markers including SMa-actin, SM myosin HC, myocardin, and desmin determined by immunofluorescence. Our date have established a simple iPS-SMC system to generate SMCs in vitro, which has tremendous potential to generate individualized SMCs for urethral tissue engineering and continence recover.

    researchmap

  • がん治療遺伝子REICによるナノバイオ標的医療の創成

    2010 - 2012

    岡山県  特別電源所在県科学技術振興事業 研究委託事業 

    公文 裕巳

      More details

    Grant type:Competitive

    researchmap

  • 局所がん病巣を標的とする革新的生物製剤治療システムの開発

    2010 - 2011

    経済産業省  地域イノベーション創出研究開発事業 

    公文 裕巳

      More details

    Grant type:Competitive

    researchmap

  • 播種性癌細胞検出・分離のための新技術の開発

    2010

    両備てい園記念財団  研究助成金 

    渡部 昌実

      More details

    Grant type:Competitive

    researchmap

▼display all